Kazia Therapeutics Files 6-K with Financial Updates
Ticker: KZIA · Form: 6-K · Filed: Jun 10, 2025 · CIK: 1075880
Sentiment: neutral
Topics: financial-reporting, sec-filing, interim-report
Related Tickers: KZIA
TL;DR
Kazia Therapeutics (KZIA) dropped a 6-K on 6/10/25 with Q2 2024 financials – check retained earnings and reserves.
AI Summary
Kazia Therapeutics Ltd. filed a 6-K report on June 10, 2025, detailing financial information for the period ending December 31, 2024. The report includes financial data for the six months ended December 31, 2024, and comparative periods. Key financial statement items such as retained earnings and reserves are presented.
Why It Matters
This filing provides investors with updated financial performance and position information for Kazia Therapeutics, crucial for evaluating the company's health and investment potential.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Numbers
- 2024-12-31 — Reporting Period End Date (The report covers financial data up to this date.)
- 2023-12-31 — Comparative Period End Date (Financial data from this prior period is included for comparison.)
Key Players & Entities
- Kazia Therapeutics Ltd. (company) — Filer of the report
- Novogen Ltd (company) — Former company name
- 0001075880 (company) — Central Index Key for Kazia Therapeutics Ltd.
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to provide updated financial information for Kazia Therapeutics Ltd., including financial statements and related disclosures for the period ending December 31, 2024.
What is the fiscal year end for Kazia Therapeutics Ltd.?
The fiscal year end for Kazia Therapeutics Ltd. is June 30 (0630).
When was Kazia Therapeutics Ltd. formerly known as?
Kazia Therapeutics Ltd. was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
What specific financial statement items are mentioned in the filing details?
The filing details mention items such as Reserve Of Sharebased Payments, Shares Subscribed But Unissued, Issued Capital, Retained Earnings, and Foreign Currency Translation Reserve.
What is the business address of Kazia Therapeutics Ltd.?
The business address of Kazia Therapeutics Ltd. is Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW, 2000.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 10, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).